Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases.
Mariangela ManfrediLieve Van HoovelsMaurizio BenucciRiccardo De LucaCarmela CocciaPamela BernardiniEdda RussoAmedeo AmedeiSerena GuiducciValentina GrossiXavier BossuytCarlo PerriconeMaria InfantinoPublished in: Journal of personalized medicine (2023)
The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.
Keyphrases
- cardiovascular disease
- oxidative stress
- multiple sclerosis
- rheumatoid arthritis
- induced apoptosis
- type diabetes
- cardiovascular events
- systematic review
- papillary thyroid
- squamous cell carcinoma
- adipose tissue
- binding protein
- coronary artery disease
- human health
- glycemic control
- metabolic syndrome
- cell proliferation
- risk assessment